Humanities
Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Psoriatic arthritis - Tofacitinib as a new treatment
  • Home
  • /
  • Psoriatic arthritis - Tofacitinib as a new treatment
  1. Home /
  2. Archives /
  3. Vol. 73 (2024) /
  4. Medical Sciences

Psoriatic arthritis - Tofacitinib as a new treatment

Authors

  • Marta Skorupska Miejskie Centrum Medyczne im. dr Karola Jonschera w Łodzi https://orcid.org/0009-0001-6556-3133
  • Magdalena Joanna Czeczotka Karol Jonscher Municipal Medical Center, Milionowa 14, 93-113 Łódź, Poland https://orcid.org/0009-0005-6306-8437
  • Martyna Magdalena Martka Karol Jonscher Municipal Medical Center, Milionowa 14, 93-113 Łódź, Poland https://orcid.org/0009-0006-2295-5459
  • Natalia Aleksandra Popławska Central Clinical Hospital of the Medical University of Lodz, Pomorska 251, 92-213 Łódź https://orcid.org/0009-0002-6243-6603
  • Justyna Śliz Central Clinical Hospital of the Medical University of Lodz, Pomorska 251, 92-213 Łódź https://orcid.org/0009-0007-0242-149X
  • Krzysztof Woźniak Medical University of Lodz, Al. Kościuszki 4, 90-419 Łódź https://orcid.org/0009-0004-1438-0806

DOI:

https://doi.org/10.12775/JEHS.2024.73.51686

Keywords

Psoriatic arthritis, Tofacitinib, JAK inhibitors, JAK-STAT

Abstract

Introduction:


JAK inhibitors are used in the treatment of psoriatic arthritis when there is a lack of effective response or intolerance to first-line drugs or their use must be discontinued due to the presence of side effects. JAK inhibitors inhibit the JAK-STAT signaling pathway which plays a significant role in the pathogenesis of many inflammatory and autoimmune diseases. This mechanism leads to a reduction in the level of pro-inflammatory cytokines which causes rapid improvement in the patient's clinical condition. Tofacitinib is the best-known drug in this group; its use carries an increased risk of cardiovascular events and reactivation of the varicella-zoster virus. Regular monitoring of patients results in faster detection of the first signs of undesirable effects and the cessation of their progression. The drug's safety profile is acceptable and the benefits outweigh possible complications.

 

Aim of  the study:

 

The aim of the study is to summarize the available knowledge about tofacitinib treatment in psoriatic arthritis. The way of work, effectiveness of treatment and potential side effects were summarized and described.

 

Materials and methods:

 

The literature available in PubMed database was reviewed using the following keywords:

“Psoriatic arthritis”, “Tofacitinib”, “JAK inhibitors”, “JAK-STAT”

 

Conclusion:

 

Tofacitinib treatment in rheumatology is used in psoriatic arthritis. The rapid improvement in the clinical condition of patients treated with JAK inhibitors is due to their direct impact on the modulation of the pathogenesis of the disease. The predictable benefits of therapy outweigh the side effects which can be detected at an early stage with regular monitoring of the patient.

References

Taylor PC, Choy E, Baraliakos X, Szekanecz Z, Xavier RM, Isaacs JD, Strengholt S, Parmentier JM, Lippe R, Tanaka Y. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology (Oxford). 2024 Feb 1;63(2):298-308. doi: 10.1093/rheumatology/kead448. PMID: 37624925; PMCID: PMC10836981. https://doi.org/10.1093/rheumatology/kead448

Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021 Jun;35(2):101692. doi: 10.1016/j.berh.2021.101692. Epub 2021 May 18. PMID: 34016528.

https://doi.org/10.1016/j.berh.2021.101692

Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017 Feb;17(1):65-70. doi: 10.7861/clinmedicine.17-1-65. PMID: 28148584; PMCID: PMC6297592.

https://doi.org/10.7861/clinmedicine.17-1-65

Sampaio-Barros PD. Epidemiology of spondyloarthritis in Brazil. Am J Med Sci. 2011 Apr;341(4):287-8. doi: 10.1097/MAJ.0b013e31820f8caf. PMID: 21358306.

https://doi.org/10.1097/MAJ.0b013e31820f8caf

Ogdie A, Weiss P. The Epidemiology of Psoriatic Arthritis. Rheum Dis Clin North Am. 2015 Nov;41(4):545-68. doi: 10.1016/j.rdc.2015.07.001. Epub 2015 Sep 11. PMID: 26476218; PMCID: PMC4610151. https://doi.org/10.1016/j.rdc.2015.07.001

Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018 Aug;48(1):28-34. doi: 10.1016/j.semarthrit.2018.01.003. Epub 2018 Jan 6. PMID: 29398124. https://doi.org/10.1016/j.semarthrit.2018.01.003

Kang Z, Zhang X, Du Y, Dai SM. Global and regional epidemiology of psoriatic arthritis in patients with psoriasis: A comprehensive systematic analysis and modelling study. J Autoimmun. 2024 May;145:103202. doi: 10.1016/j.jaut.2024.103202. Epub 2024 Mar 16. PMID: 38493674.

https://doi.org/10.1016/j.jaut.2024.103202

Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis. 2013 Apr;72(4):578-82. doi: 10.1136/annrheumdis-2012-201357. Epub 2012 May 15. PMID: 22589379.

https://doi.org/10.1136/annrheumdis-2012-201357

Kalyoncu U, Bayindir Ö, Ferhat Öksüz M, Doğru A, Kimyon G, Tarhan EF, Erden A, Yavuz Ş, Can M, Çetin GY, Kılıç L, Küçükşahin O, Omma A, Ozisler C, Solmaz D, Bozkirli ED, Akyol L, Pehlevan SM, Gunal EK, Arslan F, Yılmazer B, Atakan N, Aydın SZ; Psoriatic Arthritis Registry of Turkey Study Group. The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients. Rheumatology (Oxford). 2017 Feb;56(2):279-286. doi: 10.1093/rheumatology/kew375. Epub 2016 Oct 29. PMID: 27794533. https://doi.org/10.1093/rheumatology/kew375

Polachek A, Al-Johani R, Li S, Ye JY, Chandran V, Gladman D. Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. Semin Arthritis Rheum. 2019 Apr;48(5):834-839. doi: 10.1016/j.semarthrit.2018.08.005. Epub 2018 Aug 24. PMID: 30243758.

https://doi.org/10.1016/j.semarthrit.2018.08.005

Chandran V, Schentag CT, Brockbank JE, Pellett FJ, Shanmugarajah S, Toloza SM, Rahman P, Gladman DD. Familial aggregation of psoriatic arthritis. Ann Rheum Dis. 2009 May;68(5):664-7. doi: 10.1136/ard.2008.089367. Epub 2008 Jun 4. PMID: 18524791. https://doi.org/10.1136/ard.2008.089367

Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs. 2000 Jul;9(7):1511-22. doi: 10.1517/13543784.9.7.1511. PMID: 11060756.

https://doi.org/10.1517/13543784.9.7.1511

Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerbäck C, Gudjonsson JE, Kõks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nöthen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ, Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Gladman DD, Abecasis GR, Elder JT. Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. Am J Hum Genet. 2015 Dec 3;97(6):816-36. doi: 10.1016/j.ajhg.2015.10.019. Epub 2015 Nov 28. PMID: 26626624; PMCID: PMC4678416. https://doi.org/10.1016/j.ajhg.2015.10.019

FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015 May 7;17(1):115. doi: 10.1186/s13075-015-0640-3. PMID: 25948071; PMCID: PMC4422545. https://doi.org/10.1186/s13075-015-0640-3

Schett G, Rahman P, Ritchlin C, McInnes IB, Elewaut D, Scher JU. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022 Jun;18(6):311-325. doi: 10.1038/s41584-022-00776-6. Epub 2022 May 5. PMID: 35513599.

https://doi.org/10.1038/s41584-022-00776-6

Azuaga AB, Ramírez J, Cañete JD. Psoriatic Arthritis: Pathogenesis and Targeted Therapies. Int J Mol Sci. 2023 Mar 3;24(5):4901. doi: 10.3390/ijms24054901. PMID: 36902329; PMCID: PMC10003101.

https://doi.org/10.3390%2Fijms24054901

Roskoski R Jr. Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update. Pharmacol Res. 2023 Jan;187:106552. doi: 10.1016/j.phrs.2022.106552. Epub 2022 Nov 17. PMID: 36403719.

https://doi.org/10.1016/j.phrs.2022.106552

Norman P. Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. doi: 10.1517/13543784.2014.918604. Epub 2014 May 12. PMID: 24818516. https://doi.org/10.1517/13543784.2014.918604

McDonnell ME, Bian H, Wrobel J, Smith GR, Liang S, Ma H, Reitz AB. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors. Bioorg Med Chem Let https://doi.org/10.1016/j.bmcl.2014.01.001 t. 2014 Feb 15;24(4):1116-21. doi: 10.1016/j.bmcl.2014.01.001. Epub 2014 Jan 9. PMID: 24461299. ,

https://doi.org/10.1016/j.bmcl.2014.01.001

[Jiang JK, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, Smith J, Nguyen DT, Liu EH, Leister W, Costanzi S, O'Shea JJ, Thomas CJ. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem. 2008 Dec 25;51(24):8012-8. doi: 10.1021/jm801142b. PMID: 19053756; PMCID: PMC2660606.

https://doi.org/10.1021/jm801142b]

Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X, Ma H, Wei D, Sun S. The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol. 2020 Mar;80:106210. doi: 10.1016/j.intimp.2020.106210. Epub 2020 Jan 20. PMID: 31972425. https://doi.org/10.1016/j.intimp.2020.106210

Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec;16(12):843-862. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6. Erratum in: Nat Rev Drug Discov. 2017 Dec 28;17 (1):78. PMID: 29104284.

https://doi.org/10.1038/nrd.2017.201

Hodge JA, Kawabata TT, Krishnaswami S, Clark JD, Telliez JB, Dowty ME, Menon S, Lamba M, Zwillich S. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016 Mar-Apr;34(2):318-28. Epub 2016 Mar 10. PMID: 26966791.

Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7. PMID: 21383241; PMCID: PMC3108067.

https://doi.org/10.4049/jimmunol.1003668

Kamata M, Tada Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int J Mol Sci. 2020 Mar 1;21(5):1690. doi: 10.3390/ijms21051690. PMID: 32121574; PMCID: PMC7084606. https://doi.org/10.3390/ijms21051690

Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, Gross CJ, Dowty ME, Ramaiah SK, Hirsch JL, Saabye MJ, Barks JL, Kishore N, Morris DL. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010 Aug 11;7:41. doi: 10.1186/1476-9255-7-41. PMID: 20701804; PMCID: PMC2928212. https://doi.org/10.1186/1476-9255-7-41

Tanaka Y, Luo Y, O'Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022 Mar;18(3):133-145. doi: 10.1038/s41584-021-00726-8. Epub 2022 Jan 5. PMID: 34987201; PMCID: PMC8730299. https://doi.org/10.1038/s41584-021-00726-8

1 Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975. PMID: 29045212.

https://doi.org/10.1056/nejmoa1615975

2 Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017 Oct 19;377(16):1525-1536. doi: 10.1056/NEJMoa1615977. PMID: 29045207.

https://doi.org/10.1056/nejmoa1615977

6. Strand V, de Vlam K, Covarrubias-Cobos JA, Mease PJ, Gladman DD, Graham D, Wang C, Cappelleri JC, Hendrikx T, Hsu MA. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 2019 Jan 11;5(1):e000806. doi: 10.1136/rmdopen-2018-000806. PMID: 30713721; PMCID: PMC6340575.

https://doi.org/10.1136/rmdopen-2018-000806

van der Heijde D, Gladman DD, FitzGerald O, Kavanaugh A, Graham D, Wang C, Fallon L. Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. J Rheumatol. 2019 Sep;46(9):1089-1096. doi: 10.3899/jrheum.180971. Epub 2019 Mar 1. PMID: 30824647. https://doi.org/10.3899/jrheum.180971

Leng X, Lin W, Liu S, Kanik K, Wang C, Wan W, Jiang Z, Liu Y, Liu S, Zhang Z, Zhang Z, Xu J, Tan W, Hu J, Li J, Liu J, Gunay LM, Dina O, Kinch C, Zeng X. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. 2023 Jan;9(1):e002559. doi: 10.1136/rmdopen-2022-002559. PMID: 36720560; PMCID: PMC9890804. https://doi.org/10.1136/rmdopen-2022-002559

Wang TS, Tsai TF. Tofacitinib in psoriatic arthritis. Immunotherapy. 2017 Nov;9(14):1153-1163. doi: 10.2217/imt-2017-0087. Epub 2017 Oct 2. PMID: 28967798.

https://doi.org/10.2217/imt-2017-0087

Gratacós Masmitjà J, González Fernández CM, Gómez Castro S, Rebollo Laserna FJ. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. Adv Ther. 2021 Feb;38(2):868-884. doi: 10.1007/s12325-020-01585-7. Epub 2020 Dec 17. PMID: 33331985. https://doi.org/10.1007/s12325-020-01585-7

Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, FitzGerald O, Fleishaker D, Wang C, Wu J, Hsu MA, Menon S, Fallon L, Romero AB, Kanik KS. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Rheumatol Ther. 2020 Sep;7(3):553-580. doi: 10.1007/s40744-020-00209-4. Epub 2020 Jun 6. PMID: 32506317; PMCID: PMC7410915.

https://doi.org/10.1007/s40744-020-00209-4

Atzeni F, Popa CD, Nucera V, Nurmohamed MT. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol. 2022 Mar;18(3):233-244. doi: 10.1080/1744666X.2022.2039630. Epub 2022 Feb 17. PMID: 35129033. https://doi.org/10.1080/1744666x.2022.2039630

Kristensen LE, Strober B, Poddubnyy D, Leung YY, Jo H, Kwok K, Vranic I, Fleishaker DL, Fallon L, Yndestad A, Gladman DD. Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib. Ther Adv Musculoskelet Dis. 2023 Feb 7;15:1759720X221149965. doi: 10.1177/1759720X221149965. PMID: 36777695; PMCID: PMC9909057.

https://doi.org/10.1177/1759720x221149965

Ighani A, Georgakopoulos JR, Yeung J. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. G Ital Dermatol Venereol. 2020 Aug;155(4):400-410. doi: 10.23736/S0392-0488.20.06643-2. Epub 2020 Apr 29. PMID: 32348084.

https://doi.org/10.23736/s0392-0488.20.06643-2

Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biswas P, Jones T, Palmetto N, Hendrikx T, Menon S, Rojo R. An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data. Drug Saf. 2020 Apr;43(4):379-392. doi: 10.1007/s40264-020-00904-9. PMID: 32006348; PMCID: PMC7105422.

https://doi.org/10.1007/s40264-020-00904-9

Yang F, Lu C, Wang Y, Liu H, Leng X, Zeng X. Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2023 Jun;42(6):1593-1605. doi: 10.1007/s10067-023-06529-4. Epub 2023 Feb 10. PMID: 36763226.

https://doi.org/10.1007/s10067-023-06529-4

Downloads

  • PDF

Published

2024-06-03

How to Cite

1.
SKORUPSKA, Marta, CZECZOTKA, Magdalena Joanna, MARTKA, Martyna Magdalena, POPŁAWSKA, Natalia Aleksandra, ŚLIZ, Justyna and WOŹNIAK, Krzysztof. Psoriatic arthritis - Tofacitinib as a new treatment. Journal of Education, Health and Sport. Online. 3 June 2024. Vol. 73, p. 51686. [Accessed 7 July 2025]. DOI 10.12775/JEHS.2024.73.51686.
  • ISO 690
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 73 (2024)

Section

Medical Sciences

License

Copyright (c) 2024 Marta Skorupska, Magdalena Joanna Czeczotka, Martyna Magdalena Martka, Natalia Aleksandra Popławska, Justyna Śliz, Krzysztof Woźniak

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 337
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

Psoriatic arthritis, Tofacitinib, JAK inhibitors, JAK-STAT
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Instytut Tomistyczny
  • Karmelitański Instytut Duchowości w Krakowie
  • Ministerstwo Kultury i Dziedzictwa Narodowego
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polska Fundacja Przemysłu Kosmicznego
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Komisji Edukacji Narodowej w Krakowie
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop